Cargando…
Real-Life Pharmacokinetics of rFVIII-Fc and rFIX-Fc
Autores principales: | Traets, Marissa J.M., Fischer, Kathelijn, Uitslager, Nanda, van der Valk, Paul R., Kremer Hovinga, Idske C.L., van Vulpen, Lize F.D., Schutgens, Roger E.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649062/ https://www.ncbi.nlm.nih.gov/pubmed/33178904 http://dx.doi.org/10.1055/s-0040-1718416 |
Ejemplares similares
-
Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses
por: Kjalke, Marianne, et al.
Publicado: (2021) -
Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A
por: Chang, Chia-Yau, et al.
Publicado: (2023) -
Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII
por: Swiech, Kamilla, et al.
Publicado: (2011) -
Cost-Effectiveness Analysis of rFVIIIFc Versus Contemporary rFVIII Treatments for Patients with Severe Hemophilia A Without Inhibitors in the United States
por: Bullement, Ash, et al.
Publicado: (2021) -
Assessing prophylactic use and clinical outcomes in hemophilia A patients treated with rVIII‐SingleChain and other common rFVIII products in Germany
por: Olivieri, Martin, et al.
Publicado: (2020)